Certain HIV Treatment Less Effective When Used With Anti-TB Therapy

Patients receiving rifampicin-based anti-tuberculosis therapy are more likely to experience virological failure when starting nevirapine-based antiretroviral therapy, an HIV treatment that is widely used in developing countries because of lower cost, than when starting efavirenz-based antiretroviral therapy, according to a study in the Aug. 6 issue of JAMA, a theme issue on HIV/AIDS.

Read the whole article on Science Daily

More from Science Daily